4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶 | 937273-29-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶
• 英文名称: 4-(3-((allyloxy)methyl)phenyl)-2-chloropyrimidine
• 英文别名: 2-chloro-4-[3-(prop-2-enoxymethyl)phenyl]pyrimidine
• CAS: 937273-29-5
• 化学式: C₁₄H₁₃ClN₂O
• 分子量: 260.723
• InChiKey: SFLXQVPCWIHCJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 储存条件：
  存储条件为：2-8°C，避光，惰性气体保护。

反应信息

• 作为反应物：
  描述：

  4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶 在 盐酸 、 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethylaminosulfonyl)phenyl]methyleneruthenium(II) dichloride 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 正丁醇 为溶剂， 反应 13.0h， 生成 1-[4-(14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaen-11-yl)piperazin-1-yl]ethanone
  参考文献：
  名称：

  Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

  摘要：

  Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2(V617F)), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (ME). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2(WT) and JAK2(V617F), respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for ME and lymphoma.

  DOI：

  10.1021/jm200326p
• 作为产物：
  描述：

  3-羟甲基苯硼酸 在 四(三苯基膦)钯 、 potassium fluoride dihydrate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶
  参考文献：
  名称：

  大环类激酶抑制剂化合物、制备方法及其作为 药物的应用

  摘要：

  本发明涉及具有结构式(I)所示的化合物，其中L，R1，Z，A，B，C如本申请说明书中所定义。本发明还涉及具有结构式(I)所示的一类化合物在作为激酶抑制剂方面的应用。

  公开号：

  CN102757448B
• 作为试剂：
  描述：

  4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶 、 3-((烯丙氧基)甲基)-4-(2-(吡咯烷-1-基)乙氧基)苯胺 在 4-(3-(烯丙基氧基甲基)苯基)-2-氯嘧啶 作用下， 生成 [4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine
  参考文献：
  名称：

  WO2007058627A1

  摘要：

  公开号：

文献信息

• [EN] JAK AND HDAC DUAL-INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DOUBLES DE JAK ET DE HDAC
  申请人：NAT UNIV SINGAPORE

  公开号：WO2017196261A1

  公开（公告）日：2017-11-16

  The present disclosure described provides novel dual inhibition compounds that specifically target the JAK-STAT and HDAC pathways, two distinct cellular pathways that are useful in the treatment of various diseases and disorders. In certain aspects, the compounds described herein are useful in the treatment of cellular proliferative and inflammatory diseases or disorders, such as graft vs. host disease. In particular embodiments, the compounds described herein inhibit JAK2 and HDAC6.

  本公开的描述提供了一种新颖的双重抑制化合物，专门针对JAK-STAT和HDAC途径，这两种不同的细胞途径对治疗各种疾病和障碍很有用。在某些方面，本文描述的化合物对细胞增殖性和炎症性疾病或障碍的治疗是有用的，例如移植物抗宿主病。在特定实施例中，本文描述的化合物抑制JAK2和HDAC6。
• OXYGEN LINKED PYRIMIDINE DERIVATIVES
  申请人：Blanchard Stephanie

  公开号：US20120196855A1

  公开（公告）日：2012-08-02

  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

  本发明涉及嘧啶化合物，其作为抗增殖剂具有用处。更具体地说，本发明涉及氧连接和取代的嘧啶化合物，其制备方法，含有这些化合物的制药组合物以及这些化合物在治疗增殖性疾病方面的用途。这些化合物可用作治疗许多增殖性疾病，包括肿瘤和癌症以及与激酶相关或相关的其他疾病或病况的药物。
• HETEROALKYL LINKED PYRIMIDINE DERIVATIVES
  申请人：Blanchard Stephanie

  公开号：US20090258886A1

  公开（公告）日：2009-10-15

  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other conditions or disorders associated with kinases.

  本发明涉及用作抗增殖剂的嘧啶化合物。更具体地说，本发明涉及杂原子烷基连接和取代的嘧啶化合物，其制备方法，含有这些化合物的制药组合物以及在治疗增殖性疾病中使用这些化合物的用途。这些化合物可能作为药物对许多增殖性疾病，包括肿瘤和癌症以及与激酶相关的其他疾病或疾病的治疗有用。
• Oxygen linked pyrimidine derivatives
  申请人：CTI BIOPHARMA CORP.

  公开号：US11135227B2

  公开（公告）日：2021-10-05

  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

  本发明涉及可用作抗增殖剂的嘧啶化合物。 更具体地说，本发明涉及氧连接和取代的嘧啶化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗增殖性疾病中的用途。 这些化合物可用作治疗多种增殖性疾病的药物，包括肿瘤和癌症以及与激酶有关或相关的其他疾病或病症。
• N-大环酰胺类化合物、其制备方法及其作为药物的应用
  申请人：成都凡诺西生物医药科技有限公司

  公开号：CN115490705A

  公开（公告）日：2022-12-20

  本发明涉及具有结构通式(I)和结构通式(II)所示结构的N‑大环酰胺类化合物或其异构体、非对映体、对映体、前药、药学上可接受的盐，其中L、X、Y、Z、R1、A、B、C各自如本申请说明书中所定义。本发明还涉及具有结构通式(I)和结构通式(II)所示结构的N‑大环酰胺类化合物或其异构体、非对映体、对映体、前药、药学上可接受的盐在医药方面的应用，